Marker Therapeutics, Inc. (MRKR) — 8-K Filings

8-K Filings (25)

• 8-K Filing — Nov 14, 2025
• Marker Therapeutics Files 8-K on Director Changes and Compensation — Nov 5, 2025 Risk: low
  On October 31, 2025, Marker Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The fili
• Marker Therapeutics Files 8-K — Oct 6, 2025 Risk: low
  Marker Therapeutics, Inc. filed an 8-K on October 6, 2025, reporting other events and financial statements. The company, formerly known as TAPIMMUNE INC. and GE
• Marker Therapeutics Files 8-K — Aug 26, 2025 Risk: low
  Marker Therapeutics, Inc. filed an 8-K on August 26, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kn
• Marker Therapeutics to be Acquired by 03 Life Sciences — Aug 12, 2025 Risk: medium
  Marker Therapeutics, Inc. announced on August 7, 2025, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is ex
• Marker Therapeutics Files 8-K — Jun 17, 2025 Risk: medium
  On June 16, 2025, Marker Therapeutics, Inc. entered into a Material Definitive Agreement. The company, formerly known as TAPIMMUNE INC. and GENEMAX CORP, is bas
• Marker Therapeutics Files 8-K on Shareholder Votes & Financials — Jun 9, 2025 Risk: low
  Marker Therapeutics, Inc. filed an 8-K on June 9, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing pertai
• Marker Therapeutics Files 8-K — May 20, 2025 Risk: low
  Marker Therapeutics, Inc. filed an 8-K on May 20, 2025, reporting other events and financial statements. The company, formerly known as TAPIMMUNE INC. and GENEM
• Marker Therapeutics Files 8-K on Financials — Mar 31, 2025 Risk: low
  Marker Therapeutics, Inc. filed an 8-K on March 31, 2025, reporting on its results of operations and financial condition. The filing details the company's finan
• Marker Therapeutics Files 8-K on Shareholder Vote Matters — Mar 27, 2025 Risk: medium
  Marker Therapeutics, Inc. filed an 8-K on March 27, 2025, reporting on a submission of matters to a vote of security holders that occurred on March 21, 2025. Th
• Marker Therapeutics Appoints New CMO, Adopts Equity Plan — Feb 19, 2025 Risk: medium
  Marker Therapeutics, Inc. announced on February 12, 2025, changes in its board of directors and executive compensation. Specifically, Dr. Juan F. Vera has been
• Marker Therapeutics Announces CMO Departure, Executive Compensation Details — Jan 30, 2025 Risk: medium
  On January 24, 2025, Marker Therapeutics, Inc. announced the departure of Dr. Juan F. Vera from his role as Chief Medical Officer. The company also disclosed co
• Marker Therapeutics Files 8-K: Material Agreement & Equity Sales — Dec 23, 2024 Risk: medium
  Marker Therapeutics, Inc. announced on December 23, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales
• Marker Therapeutics Files 8-K: Material Agreement, Other Events — Dec 19, 2024 Risk: medium
  On December 19, 2024, Marker Therapeutics, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The c
• Marker Therapeutics Sells Subsidiary — Dec 17, 2024 Risk: medium
  Marker Therapeutics, Inc. announced on December 17, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Marker Therapeuti
• Marker Therapeutics Files 8-K on Financials — Nov 14, 2024 Risk: low
  Marker Therapeutics, Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition, and including financial statements
• Marker Therapeutics Files 8-K on Financials — Aug 14, 2024 Risk: low
  Marker Therapeutics, Inc. filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition, and including financial statements an
• Marker Therapeutics Sells Subsidiary, Focuses on T-cell Therapies — Aug 12, 2024 Risk: medium
  Marker Therapeutics, Inc. announced on August 12, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Marker Therapeutics
• Marker Therapeutics Sells Subsidiary to Lenders — Jun 12, 2024 Risk: medium
  Marker Therapeutics, Inc. announced on June 6, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Marker Therapeutics LL
• Marker Therapeutics Files 8-K on Financials — May 15, 2024 Risk: low
  Marker Therapeutics, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements
• Marker Therapeutics Files 8-K — Apr 8, 2024 Risk: low
  Marker Therapeutics, Inc. filed an 8-K on April 8, 2024, reporting other events and financial statements. The company, formerly known as TAPIMMUNE INC. and GENE
• Marker Therapeutics Sells Subsidiary to Catalent for $1B — Mar 26, 2024 Risk: medium
  Marker Therapeutics, Inc. announced on March 25, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Marker Therapeutics
• Marker Therapeutics Terminates Material Definitive Agreement — Mar 1, 2024 Risk: medium
  Marker Therapeutics, Inc. announced on February 29, 2024, the termination of a material definitive agreement. The company, formerly known as TAPIMMUNE INC., is
• Marker Therapeutics Enters Material Definitive Agreement — Feb 26, 2024 Risk: medium
  Marker Therapeutics, Inc. (MRKR) filed an 8-K on February 22, 2024, to report the entry into a material definitive agreement. The filing indicates a significant
• MRKR Files 8-K on Jan 8, Signals Corporate Communications Activity — Jan 8, 2024
  Marker Therapeutics, Inc. (MRKR) filed an 8-K on January 8, 2024, indicating a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX